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ABSTRACT

The compounds of the invention which encompasses a class
of compounds having the property of anti-carcinogenic
activity against human myeloma r comprising 4-oxo-2bu tenoic acid compounds and 3-hydrazino-2,4dioxobutanoic acid compounds and more specifically those
novel derivatives: 4-( 4-Chloro-phenyl)-2-(N'-fiuoren-9ylidene-hydrazino )-4-oxo-but-2-enoic acid methyl ester
(OF-07); 2-{N'-[(2-Bromo-phenyl)-phenyl-methylene ]hydrazino }-4-oxo-4-phenyl-but-2-enoic acid methyl ester
(OF-09); 2-{N'-[( 4-Dimethylamino-phenyl)-phenylmethylene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
methyl ester (OF-10) and 2-{N'-[1-( 4-Chloro-phenyl)ethylidene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
methyl ester (OF-20) and the use of 2-(N'-Fluoren-9ylidene-hydrazino )-5,5-dimethyl-4-oxo-hex-2-enoic acid
methyl ester (OF-06); 4-(4-Ethoxy-phenyl)-2-(N'-fiuoren-9ylidene-hydrazino )-2-hydroxy-4-oxo-butyric acid methyl
ester (OF-13); 4-benzoyl-3 -benzoyloxy-2-(2-oxo-2H-1,4benzoxazin-3-y l)pyrido[2,l-c ][1,4 ]benzoxazin-1,5-dione
(lF-18), 4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fiuoren-9ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19);
and 2-(N'-Fluoren-9-ylidene-hydrazino)-4-oxo-4-phenylbut-2-enoic acid methyl ester (lF-04) which are unique in
humans as therapeutic means for the eradication human
myeloma.

2 Claims, 1 Drawing Sheet
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Yonemeto, et al (U.S. Pat. No. 6,083,985) recites a
number of anti-tumor or anti-AIDS agents that include
heterocylic butenoic acid derivatives.
This invention claims the benefit of priority of U.S.
The U.S. patent literature has many disclosures of
Provisional Application Serial No. 60/296,823 filed Jun. 8,
5 butanoic acid derivatives including:
2001.
Nicolai, et al (U.S. Pat. No. 6,180,651) discloses many
FIELD OF THE INVENTION
anti-inflammatory and analgesic compounds, including
adenocarcinoma (column 1, line 55), which includes
This invention relates to compounds that are 4-oxo-2
heterocyyclic alcohol-esters (column 11, lines 1-16)
butenoic acid and 3-hydrazino-2,4-dioxobutanoic acid
and butanoic acid derivatives (many Examples includderivatives and more particularly to the use of these deriva- 10
ing 47 through 162);
tives for treatment of human myeloma.
Girard, et al (U.S. Pat. No. 5,308,852) discloses many
BACKGROUND OF THE INVENTION
compounds including butanoic acid derivatives (see
Methods B and C of schemes II and III) which comCancer is a global killer of humans with breast cancer and 15
pounds which are said to inhibit tumor metastasis
colon cancer among the leaders with many other types
(column 7, line 56 and column 8, line 4);
killing modest amounts of humans yearly including human
myeloma for which there appears to be no cure.
Frechette (U.S. Pat. No. 5,696,117), Frechette(5,854,242)
and Frechette (U.S. Pat. No. 5,707,990) describe 148
Myeloma is a cancer of plasma cells. Plasma cells are
benzoxazine and pyrido-oxazine heterocyclic as antinormally present in the bone marrow and are responsible for 20
bacterial compounds;
antibody production in response to infection and other
immune triggering events. In myeloma, a single defective
Omedi-Sale (U.S. Pat. No. 3,862,954) shows tri-azole
compounds for CNS use;
plasma cell (myeloma cell) gives rise to the much larger
number of myeloma cells which build up in the bone
Hawkins (U.S. Pat. No. 5,274,002) describes many anamarrow. This process disrupts the normal immune system as 25
logs of phenyl ethers of a substituted phenyl of the
well as displacing the normal bone marrow cells. The
formula structure at column 1, lines 49-60 with 37
myeloma cells divide and grow more frequently than normal
examples of specific compounds which compounds
plasma cells and develop cancerous properties which enable
may be useful for tumor inhibition (column 22, line
myeloma cells to invade and damage bone as well as travel
64); and,
through the blood stream to other bone marrow sites. 30
Boyd, et al (U.S. Pat. No. 6,080,790) also describes many
Because there is no known cure, treatments need to be
tri-substituted phenyl derivatives according to the forviewed in terms of how long they are able to control the
mula of the Abstract with 15 examples of specific
disease or relieve symptoms and how they affect the
compounds which may be useful for malignant skin
patient's quality of life.
diseases (column 5, line 46).
There are over 13,500 new cases of myeloma in the U.S. 35
It appears from a review of the foregoing that the oxoeach year representing 20% of blood cancers and 1% of all
butenoic derivatives of interest are not disclosed and thus
types of cancer. The incidence varies from country to
there is no report of their activity against human myeloma.
country from a low 1/100,000 in China to approximately
Consequently, there is a need for an anti-cancer drug for
4/100,000 in most Western industrialized countries.
humans that mitigates the above mentioned disadvantages of
The U.S. patent literature has many disclosures of oxo- 40 current drug therapy and effectiveness against human
butenoic ( crotonic) compounds:
myeloma.
Pamukci (U.S. Pat. No. 6,232,312) describes crotonic acid
derivatives (column 22, lines 43-58) for the treatment
SUMMARY OF THE INVENTION
of colonic polyps;
The objective of the present invention is to provide a drug
Jones et al (U.S. Pat. No. 6,121,450) discloses crotonic 45
effective for treatment of human myeloma.
acid derivatives (column 8, tine 34; column 78, line 24
Preferred embodiments of the invention encompass novel
and at example 34 as steroid modifiers in treating breast
compounds of derivatives of 4-oxo-2-butenoic acid comcancer (column 1, lines 55-58);
prising the property of anti-tumor activity against human
Kalden, et al (U.S. Pat. No. 5,334,612) discloses com50
myeloma and more specifically those novel compounds,
pounds said to be useful for treating AIDS including
alone or in admixture: OF-07; OF-09; OF-10; and OF-20
derivatives of carboxylic acid (column 9, line 31) and
and the use of the compounds: OF-06, OF-07; OF-09;
pyrrolidine (column 7, line 24);
OF-10; OF-13; OF-20; IF-04; IF-18 and, 3F-19 in humans
Brown (U.S. Pat. No. 6,066,670) describes an anti-viral
admixture containing crotonic acid for treating tumors 55 as therapeutic means for the eradication of the myeloma
carcinogens from the human's body.
(see Abstract);
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Harwell, et al (U.S. Pat. No. 5,580,896) discloses many
4-oxo-2-butenoic acid derivatives (column 13, lines
21-59; also in columns 15+, examples acid derivatives
(column 13, lines 21-59; also in columns 15+,
examples 25,26,32,34,40,43-46, 77-79,97,99,103,
106,), which are useful for inhibiting colorectal cancer,
i.e., colon cancer (Abstract);
Giordani, et al (U.S. Pat. No. 5,580,890) discloses 4-oxo2-butenoic acid derivatives said to be useful for treatment of AIDS (column 1, line 8 and column 2, line 61;
and,

60

Further objects and advantages of this invention will be
apparent from the following detailed description of presently
preferred embodiments which are illustrated structurally in
the accompanying drawings.
BRIEF DESCRIPTION OF THE FIGURES

65

FIG. 1 illustrates structurally a chemical compound designated as OF-07.
FIG. 2 illustrates structurally a chemical compound designated as OF-09.
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FIG. 3 illustrates structurally a chemical compound designated as OF-10.
FIG. 4 illustrates structurally a chemical compound designated as OF-20.

(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl
ester (3F-19); and 2-(N'-Fluoren-9-ylidene-hydrazino)4-oxo-4-phenyl-but-2-enoic acid methyl ester (lF-04).
These compounds have very high activity against
5 myeloma and a very low toxicity as Lethal Dose 50 (LD 50 )
DESCRIPTION OF THE PREFERRED
in animals. The percent activity and animal toxicity for each
EMBODIMENTS
compound is as follows: OF-06 (82% against human
Before explaining the disclosed embodiments of the
myeloma and LD 50 >3000 mg/kg); OF-07 (74% against
present invention in detail, it is to be understood that the
invention is not limited in its application to the details of the 10 human myeloma and LD 50 >750 mg/kg); OF-09 (86%
against human myeloma and LD 50 >5000 mg/kg); OF-10
particular arrangement shown since the invention is capable
(96%
against human myeloma and LD 50 >1500 mg/kg);
of other embodiments. Also, the terminology used herein is
OF-13 (99% against human myeloma and LD 50 >1500
for the purpose of description and not of limitation.
mg/kg); OF-20 (84% against human myeloma and LD 50 >250
As earlier recited this application has been filed in order
to both disclose: the novel derivatives of and the specified 15 mg/kg); lF-04 (77% against human myeloma and
LD 50 >1000 mg/kg) and lF-18 (100% against human
derivatives of 4-oxo-2-butenoic acid and the 3-hydrazinomyeloma, and LD 50 >2000 mg/kg); and 3F-19 (100% against
2,4-dioxobutanoic acid that are useful for the in vitro treathuman myeloma and LD 50 >200 mg/kg).
ment of human beings inflicterd with myeloma.
To facilitate a full understanding of the invention:
PREPARATION OF (OF-07)
the compound designated as OF-07 4-( 4-Chloro-phenyl)- 20
2-(N'-fl uoren-9-y lidene-hydrazino )-4-oxo-but-2-enoic
EXAMPLE 1
acid methyl ester;
the compound designated as OF-09 is 2-{N'-[(2-BromoThe preparation of 4-(4-Chloro-phenyl)-2-(N'-fluoren-9pheny 1)-pheny 1-methy lene ]-hydrazino }-4-oxo-425 ylidene-hydrazino )-4-oxo-but-2-enoic acid methyl ester
phenyl-but-2-enoic acid methyl ester;
(OF-07). A solution of 5.0 g (0.0208 moles) 4-( 4-chlorothe compound designated as OF-10 is 2-{N'-[(4phenyl)-2-hydroxy-4-oxo-but-2-enoic acid methyl ester (1)
Dime thylamino-phenyl)-phenyl-methylene ]and 3.88 g (0.02 moles) of fluoren-9-ylidene-hydrazine (2)
hydrazino }-4-oxo-4-phenyl-but-2-enoic acid methyl
in 50 mL of absolute toluene was refluxed for 2 hr with a
ester; and,
Dean-Stark trap (the end of the reaction was determined by
the compound designated as OF-20 is 2-{N'-[1-(4- 30
TLC). The resulting mixture was cooled, precipitate was
Chloro-phenyl)-ethy lidene ]-hydrazino }-4-oxo-4filtered and recrystallized from benzene-heptene mixture
phenyl-but-2-enoic acid methyl ester.
(1:5) to give 5.80 g (67% yield) of orange-brown crystalls
As well as the compounds recited above, those found to have
with mp 167-168° C.
use for the treating of human myeloma also include:
35
Solubility: highly soluble in DMSO, DMFA,
2-(N'-Fluoren-9-ylidene-hydrazino)-5,5-dimethyl-4-oxodichloroethane, acetonitrile, insoluble in water.
hex-2-enoic acid methyl ester (OF-06); 4-( 4-Ethoxy-

Cl--o-CO-CH=1-coocH3

+

OH

Cl--o-CO-CH=1-coocH3
NH

-

OF-07

I

a=o
N

A

pheny 1)-2-(N' -fl uoren-9-y lidene-hydrazino )-2hydroxy-4-oxo-butyric acid methyl ester (OF-13);
4- be nzoyl-3- be nzoyloxy-2-( 2-o xo -2H-1,4benzoxazin-3-y l)pyrido[2, 1-c ][1,4 ]benzoxazin-1,5dione (lF-18), 4-Chloro-4-( 4-ethoxy-pheny 1)-2-

B

PREPARATION OF (OF-09)
65

EXAMPLE 2
The preparation of 2-{N'-[(2-Bromo-phenyl)-phenylmethylene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
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methyl ester (OF-09). A solution of 6.0 g (0.0291 moles) of
2-hydroxy-4-oxo-4-phenyl-but-2-enoic acid methyl ester (1)
and 5.71 g (0.0291 moles) of [(2-Bromo-phenyl)-phenylmethylene ]-hydrazine (2) in 80 mL of absolute toluene (1:1)
was refluxed with a Dean-Stark trap (the end of the reaction 5
was determined by TLC), cooled and the precipitate was
filtered and recrystallized from benzene to give 10.24 g
(76% yield) of colorless crystals with mp 119-120° C.
Solubility: highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile, insoluble in water.

-continued

Oyycoom, Oyym='

ifo
0

/NH

---------

ocrn

&\)
0

/N

10

PREPARATION OF (OF-10)
15
+

EXAMPLE 3
20

2

The preparation of 2-{N'-[( 4-Dimethylamino-phenyl)phenyl-methylene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic
acid methyl ester (OF-10). A solution of 1.0 g (0.0048
moles) of 2-hydroxy-4-oxo-4-phenyl-but-2-enoic acid
25 methyl ester (1) and 1.16 g (0.0048 moles) of [3(Hydrazono-phenyl-methyl)-phenyl]-dimethyl-amine (2) in
30 mL of absolute benzene was refluxed with a Dean-Stark
trap (the end of the reaction was determined by TLC), cooled
and the precipitate was filtered and recrystallized from
30 benzene-hexane mixture (4:1) to give 1.18 g (61 % yield) of
yellow crystals with mp 159-160° C.

+

2

-------OF-10

Solubility: highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile, chloroform, insoluble in water.
60

PREPARATION OF (OF-20)
EXAMPLE 4

65

The preparation of 2-{N'-[1-( 4-Chloro-pheny 1)ethylidene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
methyl ester (OF-20). A solution of 6.0 g (0.0291 moles) of
methyl phenyl-2-hydroxy-4-oxo-4-phenyl-2-butenoate (1)
and 4.91 g (0.0291 moles) of [1-(4-Chloro-phenyl)-

US 6,686,496 Bl
7
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ethylidene ]-hydrazine (2) in 50 mL of absolute benzene) was
refluxed for 15 min with a Dean-Stark trap (the end of the
reaction was determined by TLC) and cooled. The resulting
precipitate was filtered and recrystallized from benzenehexane mixture (5:1) to give 4.36 g (42% yield) of yellow
crystals with mp of 116-117° C. (deco mp).
Solubility: highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile, chloroform, insoluble in water.

Solubility: highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile, insoluble in hexane. The compound is not stable in solutions and decomposes quickly
when the solution is heated or stored for a long time with the
formation of OF-12.

5

PREPARATION OF (IF-18)
EXAMPLE 7
10

+

15

* A detailed synthesis of compound 4 has been published earlier in: Five20 membered-ring 2,3-dioxoheterocycles. XXXIII. Synthesis of 3-aroyl-1,2dihydro-4H-pyrrolo[ 5,1-c ][1,4]benzoxazine-1,2,4-triones and their reaction
with water and alcohols. Mashivets, A. N.; Mashevskaya, I. V; Krasnykh, 0.
P.; Shurov, S. N.; Andreichikov, V S. Perm. Gos. Univ., Perm, Russia. Zh.
Org. Khim. (1992),
** Content: 73.5% phenyl ether 26.5% diphenyl Described in L.Fieser,
M.Fieser, Reagents for Organic Synthesis, Wiley, New York, 1968.
25

2

~

~COOCH3

0

PREPARATION OF (3F-19)

,.NH

~CH3

The preparation of 4-benzoyl-3-benzoyloxy-2-(2-oxo2H-1,4-benzoxazin-3-yl)pyrido[2,l-c ][1,4 ]benzoxazin-1,5dione (IF-18).
A solution of 1.5 g (0.047 moles) of compound 4* in 10
mL of dowtherm A** was kept at constant temperature at
183-186° C. for 30 min. The solution was cooled and the
resulting precipitate of lF-18 was filtered and recrystallized
from acetonitrile to give 0.79 g (54%) of orange crystals
with mp of 259-261° C. (decomposed).

EXAMPLE 8

OF-20
30

c1.V

PREPARATION OF (OF-06).

35

EXAMPLE 5
The preparation of 2-(N'-Fluoren-9-ylidene-hydrazino)-5,
5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06). A
solution of 5.0 g (0.02 moles) of 2-hydroxy-5,5-dimethyl4-oxo-hex-2-enoic acid methyl ester (1) (synthesis was
previously published by E. Royals. JAm.Chem.Soc., 1945,
67, 1508) and 3.88 g (0.02 moles) of fluoren-9-ylidenehydrazine (2) in 80 mL of absolute toluene was refluxed for
3 hr 30 min with a Dean-Stark trap (control for the end of
the reaction was carried by TLC). The solution was cooled
and the precipitate was filtered and recrystallized from
absolute benzene-hexane (1:1) to give 3.4 g (68% yield) of
yellow crystals, mp 135-137° C.
Solubility : highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile, slightly soluble in ethanol,
tetrachloromethane, insoluble in hexane and water.
The synthesis of OF-06 is an example of well known
amination/dehydration reactions.
PREPARATION OF (OF-13)

40

45

PREPARATION OF (IF-04)
EXAMPLE 9
50

55

EXAMPLE 6
The preparation of 4-( 4-Ethoxyphenyl)-2-(N'-fluoren-9ylidene-hydrazino )-2-hydroxy-4-oxobutyric acid methyl
ester (OF-13). A solution of 5.0 g (0.02 moles) of methyl
4-p-ethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and
3.88 g (0.02 moles) of fluorene-9-ylidene-hydrazine (2) in
80 mL of absolute benzene and absolute toluene (1:1) was
refluxed for 1 hr 30 min with a Dean-Stark trap (the end of
the reaction was determined by TLC), cooled and the
precipitate was filtered and recrystallized from benzenediethyl ether-hexane mixture (1:3:2) to give 2.65 g (53%
yield) of colorless crystals with mp 114-116° C.

The preparation of 4-Chloro-4-( 4-ethoxy-phenyl)-2(fluoren-9-ylidene-hydrazono )-but-3-enoic acid methyl
ester (3F-19) To the solution of 10 g (0.0026 moles) of
4-( 4-Ethoxy-pheny1)-2-(N'-fluoren-9-ylidene-hydrazino )-4oxo-but-2-enoic acid methyl ester (1) (synthesis was previously published by Miles et.al., UCF-311A) in 5 mL of
anhydrous benzene 0.3935 g (0.0031 moles) oxalyl chloride
was added. The reaction mixture was refluxed for 1 hour 40
min, cooled, the precipitate was filtered and recrystallized
from absolute benzene to give 0.62 g (54%) of yellow
crystals, m.p. 163-163 (decamp).
A synthesis of compound 3F-19 has been published
earlier in: Konyukhova, N. A; Kiasnykh, 0. P.; Aliev, Z. G.;
Maslivets, A N. Chemistry of Heterocyclic Compounds
(New York, N.Y., United States)(Translation of Khimiya
Geterotsiklicheskikh Soedinenii) (2001), 37(6), 779-780)

60

65

The preparation of 2-(N'-Fluoren-9-ylidene-hydrazino)-4oxo-4-phenyl-but-2-enoic acid methyl ester (lF-04). A solution of 5.0 g (0.0242 moles) 4-phenyl-2-hydroxy-4-oxo-but2-enoic acid methyl ester (1) and 4.70 g (0.0242 moles) of
fluoren-9-ylidene-hydrazine (2) in 30 mL of toluene was
refluxed for 2.5 hr with a Dean-Stark trap (the end of the
reaction was determined by TLC). The resulting mixture
was cooled, precipitate was filtered and recrystallized from
hexane to give 5.83 g (63% yield) of orange-brown crystalls
with mp 133-134 ° C.
Solubility: highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile, insoluble in water.
The synthesis of OF-06 is an example of well known
amination/dehydration reactions.
A synthesis of compound lF-4 has been published earlier in:
Andrejchikov, Yurij S.; Maslivets, Andrej N.; Krasnykh,
Olga P.; Aleksandrova, Galina A; Vozhakova, Alla V. Russ.
(1993), CODEN: RUXXE7 RU 2003655 Cl 19931130
Application: RU 91-5013322 19910704

US 6,686,496 Bl
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TABLE 1
Compounds claimed for use in treatment of myeloma only.

Name

Structure

Activity
(ATCC CCL155)

LDso
mg/kg Reference

OF-06

2-(N'-Fluoren-9-ylidenehydrazino)-5,5-dimethyl4-oxo-hex-2-enoic acid
methyl ester

82%

>3000 Miles et. al., UCF-311A

OF-13

4-( 4-Ethoxy-phenyl)-2-(N' fluoren-9-ylidenehydrazino)-2-hydroxy-4oxo-butyric acid methyl

99%

>1500 Miles et. al., UCF-303A

100%

>2000 Miles et. al., UCF-303B

100%

>200 Konyukhova, N. A.;
Krasnykh, 0. P.;
Aliev, Z. G.;
Maslivets, A. N.
Chemistry of Heterocyclic Compounds
(New York, NY,
United States) (2001),
37(6), 779-780.

ester

IF-18

Benzoic acid 1-benzoyl4,10-dioxo-3-(2-oxo-2Hbenzo[1,4]oxazin-3-yl)4,4b,8a,10-tetrahydro-9-

0

COC6Hs

oxa-4a-aza-phenanthren-2-

yl ester
0
0

OCOC6Hs

OD
~N

I#

3F-19

C2HsO
0

IF-04

4-Chloro-4-( 4-ethoxyphenyl)-2-(fluoren-9ylidene-hydrazono)-but-3enoic acid methyl ester

2-(N'-Fluoren-9-ylidenehydrazino)-4-oxo-4phenyl-but-2-enoic acid
methyl ester

0

/NH
N

oCo

93%

>1000 Andrejchikov, Yurij S.;
Maslivets, Andrej N.;
Krasnykh, Olga P.;
Aleksandrova, Galina A.;
Vozhakova, Alla V Russ.
(1993), CODEN:
RUXXE7 RU 2003655
Cl 19931130
Application:
RU 91-5013322
19910704.

US 6,686,496 Bl
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CYTOTOXICITY ASSAY
The anticancer activity against human myeloma of the
novel compounds (as earlier reported) was realized by the
following procedure which determines the inhibitory effect
of test samples on the growth of human myeloma cells.
The anti-carcinogenic activity against human cancer of
the novel compounds (as earlier reported) was realized by
the following procedure which determines the inhibitory
effect of test samples on the growth of human breast cancer
cells.
(ATCC CCL155) The CCL155 cells are grown in RPMI
1640 media+20% Fetal bovine serum+4.5 g/L glucose+lO
mM HEPES+ 1.0 mM sodium pyruvate+ 1% Antibiotic/
Antimycotic for approximately 48 hours at 37° C./5% C0 2
in the presence of the test compound.
Growth/Non-Growth of the cells (e.g., cell density) is
determined using Promega's MTS/PMS assay system. MTS
(3-( 4,5-dime thylthiazol-2-yl)-5-(3carboxymethoxypheny1)-2-(4-sulfopheny l)-2H-tetrazolium,
inner salt) is an aqueous compound that is reduced to soluble
formazan by the presence of NADH formed by dehydrogenases present within the CCL155 cells. The absorbance of
the formazan can be measured at 490 nm and is directly
proportional to the number of living cells present in the
culture. PMS (Phenazine Methosulfate) is added an electron
coupling reagent and greatly increases the rate of reduction.
To facilitate a full understanding of the procedure the
following definitions are offered:
Test wells-wells containing test sample and Diluted
CCL155 cells
Test values-absorbance of test wells
Blank wells-wells containing test sample and CCL155
media (C155-01S); used to obtain background absorbance due to test sample
Blank values-absorbance of blank wells
Negative Control-maximal cell growth; results of test
samples will be expressed as a percent of the Negative
Control
Positive Control-known inhibitor of CCL155 cells; used
to validate assay system
Matrix-solvent that the samples are prepared/diluted in
Assay samples of similar origin and matrix (e.g., methanol extraction, methylene chloride extraction, water soluble
samples, etc.) together on the same plate in order to reduce
the number of steps performed per plate.
Blank values will be determined for each sample to
account for any color contribution due to the sample itself.
These blank wells must contain the same amount of sample
plus CCL155 media (no cells). After completion of MTS/
PMS reaction blank values will be subtracted from the test
value to obtain a net absorbance that will be used to calculate
cell density.
All results are based upon a comparison to the Negative
Control value of the plate. The Negative Control must
contain the same amount of matrix (e.g., solvent) to offset
any destructive effect the matrix may have on the growth of
the CCL155 cells (allows for baseline values to be set).
For most samples, a CCL155 cell growth (initial density
of 120,000 to 160,000 cells/ml) of approximately 48 hours
followed by and incubation of 2 hours with the MTS/PMS
Reagent is optimal.
In order to establish the accuracy of this assay a Positive
Control consisting of 50 µM Methotrexate should not
decrease the net absorbance to less than 90% of the Negative
Control (CCL155 cells are somewhat resistant to
methotrexate) is utilized.

In order to establish the accuracy of this assay a Positive
Control consisting of 50 µM Methotrexate should show less
than 75% of the net absorbance of the Negative Control is
utilized.
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ANIMAL TOXCITY BIOASSAY
Acute toxicity was studied on white mice of both sexes
with weight ranging between 18-26 grams under intraperitoneal injection of 2% solution of tested compound in starch
(the compound was dissolved in starch slime and injected)
on the basis of 0.1 ml of solution per 10 g of the animal
weight. Each dose was tested on the group of 6 animals that
were observed during 14 days period. (This method was
approved by the Pharmacology committee of Russian Ministry of Health and has been widely used since 1968.)
Averaged lethal dose (LD 50 ) of the compound was computed using results of experiments on 5-7 groups of animals
using method of Litchfield and Wilkinson. (Belenkii M. L.
"Elements of quantative determination of the pharmacological effect," Leningrad, 1963, 71 page).
USE OF THE INVENTION FOR TREATMENT
OF HUMAN MYELOMA
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The compounds of the invention facilitate disclosure of
compounds having the property of anti-tumor activity
against human myeloma including: 4-( 4-Chloro-phenyl)-2(N'-fiuoren-9-ylidene-hydrazino )-4-oxo-but-2-enoic acid
methyl ester (OF-07); 2-{N'-[(2-Bromo-phenyl)-phenylmethylene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
methyl ester (OF-09); 2-{N'-[( 4-Dimethylamino-phenyl)phenyl-methylene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic
acid methyl ester (OF-10) and 2-{N'-[1-( 4-Chloro-phenyl)ethylidene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
methyl ester (OF-20); 2-(N'-Fluoren-9-ylidene-hydrazino)5,5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06);
4-( 4-Ethoxy-pheny1)-2-(N'-fiuoren-9-ylidene-hydrazino )-2h ydro xy-4-o x o -bu tyri c acid methyl ester (OF-13);
4-benzoyl-3-benzoy loxy-2-(2-oxo-2H-1,4-benzoxazin-3-y1)
pyrido[2,l-c ][ 1,4 ]benzoxazin-1,5-dione (lF-18), 4-Chloro4-( 4-ethoxy-phenyl)-2-(fiuoren-9-ylidene-hydrazono)-but3-enoic acid methyl ester (3F-19); and 2-(N'-Fluoren-9ylidene-hydrazino )-4-oxo-4-phenyl-but-2-enoic acid methyl
ester (lF-04) which are unique in humans as therapeutic
means for the eradication human myeloma can be used in a
pharmaceutical composition comprising a non-toxic effective amount of the referenced compound or a tautomeric
form thereof or a pharmaceutically acceptable salt thereof or
pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier thereof.
For administration to man in the curative or prophylactic
treatment of human myeloma in vitro dosages of compounds
of the invention will generally be in the range of from 5 to
500 mg daily for an average adult patient (70 kg). Thus for
a typical adult patient, individual tablets or capsules contain
from 2-500 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in
single or multiple doses, once or several times per day.
Dosages for intraveneous, buccal or sublingual administration will typically be within the range of from 5-1000 mg
per single dose as required. In practice the physician will
determine the actual dosing regimen which will be most
suitable for an individual patient and it will vary with the
age, weight and response of the particular patient. The above
dosages are exemplary of the average case but there can be
individual instances in which higher or lower dosage ranges
may be merited, and such are within the scope of this
invention.
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The maximum human non-toxic one time administration
dose for the compound(s) of the invention appears to be
from 100 to 1000 mg.
For human use, the compounds of the invention can be
administered alone or jointly, but will generally be administered in admixture with a pharmaceutical carrier selected
with regard to the intended route of administration and
standard pharmaceutical practice. For example, they may be
administered orally, buccally or sublingually, in the form of
tablets containing excipients such as starch or lactose, or in
capasules or ovules either alone or in admixture with
excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. The compounds may also
be injected parenterally, for example intraveneously,
intramuscularly, subcutaneously or intracoronarily. For
parenteral administration, they are best used in the form of
a sterile aqueous solution which may contain other
substances, for example enough salts or glucose to make the
solution isotonic with blood.
The invention thus provides a method for the treatment of
myeloma in a human mammal which comprises administering an effective, non-toxic, amount of a compound
according to the invention or a tautomeric form thereof
and/or a pharmaceutically acceptable salt thereof and/or a
pharmaceutically acceptable solvate thereof, to a myeloma
invaded human mammal in need thereof.

The oral Melphalan-Prednisone regime has an associated
risk of secondary leukemia and care must be taken and
potential side effects explained to the patients (especially in
the younger age group).
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ADVANTAGES OF THE INVENTION
Melphalan/Prednisone combination still remains the first
line treatment for myeloma. There is no survival advantage
when MP (Melphalan-Prednisone) is compared with other
various intravenous combination chemotherapeutic agents,
e.g. VAD (Vincristine, Adriamycin, Decadron). Toxicity for
Melphalan: LD50 in mice 23 mg/kg, it should be compared
with the toxicity in the range 1000--1500 mg/kg for the
claimed compounds. Claimed compounds have toxicity at
least 50 times lower.
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Claimed compounds create a basis for further development of the anti-myeloma drugs with lower toxicity and less
side effects.
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope
of the invention is not intended to be, nor should it be
deemed to be, limited thereby and such other modifications
or embodiments as may be suggested by the teachings herein
are particularly reserved especially as they fall within the
breadth and scope of the claims here appended.
We claim:
1. A derivative of a 4-oxo-2-butenoic acid having the
property of anti-myeloma activity, wherein said derivative is
selected from the group consisting of:
4-(4-Chloro-pheny1)-2-(N'-fiuoren-9-ylidene-hydrazino )4-oxo-but-2-enoic acid methyl ester:
2-{ N' -[ (2-B romo-phenyl)-phenyl-me thylene ]hydrazino }-4-oxo-4-phenyl-but-enoic acid methyl
ester;
2-{N'-[ ( 4-Dimethy lamino-phenyl)-pheny 1-methy lene ]hydrazino }-4-oxo-4-phenyl-but-2-enoic acid methyl
ester; and
-2-{N'-[1-( 4-Chloro-phenyl)-ethylidene ]-hydrazino }-4oxo-4-phenyl-but-2-enoic acid methyl ester.
2. A method of treating myeloma in a human being in need
of such treatment, comprising administering to said human
being one or more derivatives of 4-oxo-2-butenoic acid
according to claim 1.
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